Tata India Pharma & Healthcare Fund Regular Growth is a Sector - Healthcare mutual fund scheme from Tata Asset Management Pvt Ltd. The fund was launched on 28 December 2015 and is managed by Rajat Srivastava. As of 9 October 2026, the fund has an AUM of ₹1,565.28 Cr and its latest NAV is ₹31.31. The fund has a Very High Risk risk rating.
The fund allows minimum SIP of ₹100 and lumpsum investment starting from ₹5,000.
The fund primarily invests in Healthcare, Basic Materials, and Consumer Defensive and its top holdings include Sun Pharmaceuticals Industries Ltd, Abbott India Ltd, HealthCare Global Enterprises Ltd, Divi's Laboratories Ltd, and GlaxoSmithKline Pharmaceuticals Ltd. The fund has delivered 2.5% returns over the last 1 year, 16.2% annualised returns over 3 years, 11.9% annualised returns over 5 years, and 11.2% annualised returns since inception.
Tata India Pharma & Healthcare Fund Regular Growth may be suitable for investors looking for Sector - Healthcare and who are comfortable with Very High Risk risk.






